Anupam Rasayan Expands into Pharma with Bliss GVS Stake Acquisition

Anupam Rasayan India Limited is set to acquire a significant controlling stake, ranging from 43.3% to 48.2%, in Bliss GVS Pharma Limited, an established Indian pharmaceutical formulations company.

Strategic Diversification into Pharmaceuticals

This acquisition marks a strategic move for Anupam Rasayan, a specialty chemicals firm, as it diversifies its business interests by entering the pharmaceutical sector. Bliss GVS Pharma, founded in 1984, operates six manufacturing facilities and possesses various global accreditations, indicating a strong operational base and market presence.

Bliss GVS Pharma's Financial Health

As of March 31, 2026, Bliss GVS Pharma reported a robust financial position. The company held ₹167 Crores in cash and cash equivalents and generated ₹139 Crores in cash flow from operations. Notably, Bliss GVS Pharma maintained zero net debt.

Funding the Acquisition

Anupam Rasayan is financing this acquisition through a combination of debt and equity. Approximately ₹300 Crores will be sourced from a term loan, with the remainder funded by a non-controlling, non-voting equity instrument.

Future Outlook and Potential Challenges

Anupam Rasayan's management will aim to integrate Bliss GVS Pharma's operations and leverage its pharmaceutical expertise. Investors will monitor the success of this integration and how Bliss GVS Pharma contributes to Anupam Rasayan's overall growth and revenue streams. Potential challenges include integrating operations and ensuring market acceptance of the diversification strategy.

Key Metrics of the Deal

• Acquisition Stake: 43.3% to 48.2% controlling stake in Bliss GVS Pharma.
• Funding: Approximately ₹300 Crores via a term loan, plus other equity instruments.
• Bliss GVS Pharma Financials (as of March 31, 2026): ₹167 Crores in cash and cash equivalents, ₹139 Crores in operating cash flow, and zero net debt.